Bifogade filer
PDF
Kurs
+0,16%
Kalender
| Est. tid* | ||
| 2025-02-18 | - | Bokslutskommuniké 2024 |
| 2024-11-19 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-20 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-07 | - | X-dag ordinarie utdelning CALMA B 0.00 SEK |
| 2024-06-05 | - | Årsstämma |
| 2024-05-21 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-20 | - | Bokslutskommuniké 2023 |
| 2023-12-14 | - | Extra Bolagsstämma 2023 |
| 2023-11-21 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-22 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-23 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-17 | - | X-dag ordinarie utdelning CALMA B 0.00 SEK |
| 2023-05-16 | - | Årsstämma |
| 2023-02-21 | - | Bokslutskommuniké 2022 |
| 2022-11-22 | - | Kvartalsrapport 2022-Q3 |
| 2022-09-22 | - | Extra Bolagsstämma 2022 |
| 2022-08-23 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-24 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-19 | - | X-dag ordinarie utdelning CALMA B 0.00 SEK |
| 2022-05-17 | - | Årsstämma |
| 2022-02-25 | - | Bokslutskommuniké 2021 |
| 2022-02-23 | - | Bokslutskommuniké 2021 |
| 2021-10-29 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-27 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-28 | - | Kvartalsrapport 2021-Q1 |
| 2021-05-19 | - | X-dag ordinarie utdelning CALMA B 0.00 SEK |
| 2021-05-18 | - | Årsstämma |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-12-23 | - | Extra Bolagsstämma 2020 |
| 2020-11-25 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-20 | - | Kvartalsrapport 2020-Q1 |
| 2020-05-15 | - | X-dag ordinarie utdelning CALMA B 0.00 SEK |
| 2020-05-14 | - | Årsstämma |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-25 | - | Kvartalsrapport 2019-Q3 |
| 2019-11-06 | - | Extra Bolagsstämma 2019 |
| 2019-08-27 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-23 | - | Kvartalsrapport 2019-Q1 |
| 2019-05-10 | - | X-dag ordinarie utdelning CALMA B 0.00 SEK |
| 2019-05-09 | - | Årsstämma |
| 2019-02-28 | - | Bokslutskommuniké 2018 |
| 2018-11-26 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-27 | - | Kvartalsrapport 2018-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Calmark Sweden AB (publ) announced today that the company has initiated measures to streamline the internal organization and to prioritize the sales of the company's fully developed products. The development projects for new biomarkers are paused until further notice and the organization is thus reduced by 25%. The ambition is for Calmark to become cash flow positive in the coming year.
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
This disclosure contains information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 28-11-2022 09:45 CET.
Camilla Arneving, Acting CEO
Telefon: +46 (0)10 204 01 50
E-post: camilla.arneving@calmark.se
www.calmark.se